Contineum Therapeutics, Inc. (CTNM)

Market Cap	354.09M
Revenue (ttm)	50.00M
Net Income (ttm)	3.15M
Shares Out	25.13M
EPS (ttm)	0.08
PE Ratio	176.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,564
Open	14.90
Previous Close	14.90
Day's Range	13.65 - 15.15
52-Week Range	13.65 - 16.06
Beta	n/a
Analysts	Strong Buy
Price Target	28.00 (+98.72%)
Earnings Date	May 16, 2024

About CTNM

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple scl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2024
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: CTNM

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 3 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 98.72% from the latest price.

Price Target

$28.0

(98.72% upside)

Analyst Consensus: Strong Buy